Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Jun 9. doi: 10.1007/s00280-018-3619-3. [Epub ahead of print]

PMID:
29948021
2.

Graft Versus Host Disease of the Central Nervous System after Liver Transplantation: A Rare Complication.

Pahari H, Nagai S, Skorupski S, Salgia R.

Am J Transplant. 2018 Jun 23. doi: 10.1111/ajt.14981. [Epub ahead of print]

PMID:
29935052
3.

Chances of Renal Recovery or Liver Transplantation After Hospitalization for Alcoholic Liver Disease Requiring Dialysis.

Lenhart A, Hussain S, Salgia R.

Dig Dis Sci. 2018 Jun 22. doi: 10.1007/s10620-018-5170-9. [Epub ahead of print]

PMID:
29934721
4.

Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P.

J Clin Med. 2018 Jun 17;7(6). pii: E156. doi: 10.3390/jcm7060156. Review.

5.

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M.

Oncotarget. 2018 May 25;9(40):26226-26242. doi: 10.18632/oncotarget.25360. eCollection 2018 May 25. Review.

6.

Managing Patients With Relapsed Small-Cell Lung Cancer.

Gong J, Salgia R.

J Oncol Pract. 2018 Jun;14(6):359-366. doi: 10.1200/JOP.18.00204.

PMID:
29894664
7.

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.

Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R.

Oncotarget. 2018 Apr 13;9(28):19793-19806. doi: 10.18632/oncotarget.24857. eCollection 2018 Apr 13.

8.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
9.

2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.

Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS.

Oncotarget. 2018 Apr 6;9(26):18053-18068. doi: 10.18632/oncotarget.24720. eCollection 2018 Apr 6.

10.

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R.

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032. No abstract available.

PMID:
29685646
11.

Value-based genomics.

Gong J, Pan K, Fakih M, Pal S, Salgia R.

Oncotarget. 2018 Jan 30;9(21):15792-15815. doi: 10.18632/oncotarget.24353. eCollection 2018 Mar 20. Review.

12.

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.

Mambetsariev I, Vora L, Yu KW, Salgia R.

BMC Cancer. 2018 Mar 21;18(1):314. doi: 10.1186/s12885-018-4222-z.

13.

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M.

Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048. Epub 2018 Mar 15.

PMID:
29551267
14.

Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).

Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):177-185. doi: 10.1016/j.ijrobp.2018.01.046. Epub 2018 Jan 31.

PMID:
29487024
15.

The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer.

Salgia R, Kulkarni P.

Trends Cancer. 2018 Feb;4(2):110-118. doi: 10.1016/j.trecan.2018.01.001. Epub 2018 Feb 3. Review.

PMID:
29458961
16.

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.

Amanam I, Gupta R, Mambetsariev I, Salgia R.

Future Oncol. 2018 Feb 16. doi: 10.2217/fon-2017-0545. [Epub ahead of print]

PMID:
29451020
17.

EphB4: A promising target for upper aerodigestive malignancies.

Salgia R, Kulkarni P, Gill PS.

Biochim Biophys Acta. 2018 Apr;1869(2):128-137. doi: 10.1016/j.bbcan.2018.01.003. Epub 2018 Jan 31. Review.

PMID:
29369779
18.

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R.

J Immunother Cancer. 2018 Jan 23;6(1):8. doi: 10.1186/s40425-018-0316-z. Review.

19.

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.

Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R.

Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.

20.

Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States.

Jinjuvadia R, Salami A, Lenhart A, Jinjuvadia K, Liangpunsakul S, Salgia R.

Am J Med Sci. 2017 Oct;354(4):362-369. doi: 10.1016/j.amjms.2017.05.016. Epub 2017 Jun 1.

PMID:
29078840
21.

State-of-the-art considerations in small cell lung cancer brain metastases.

Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R.

Oncotarget. 2017 Jul 18;8(41):71223-71233. doi: 10.18632/oncotarget.19333. eCollection 2017 Sep 19. Review.

22.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.

Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M.

Oncotarget. 2017 Jun 28;8(40):67639-67650. doi: 10.18632/oncotarget.18797. eCollection 2017 Sep 15.

23.

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.

Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J.

Oncotarget. 2017 Sep 22;8(37):62817. doi: 10.18632/oncotarget.20632. eCollection 2017 Sep 22.

24.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.

BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.

25.

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.

Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R.

Sci Rep. 2017 Aug 23;7(1):9192. doi: 10.1038/s41598-017-09078-4.

26.

Outcome of liver transplantation in patients with prior bariatric surgery.

Safwan M, Collins KM, Abouljoud MS, Salgia R.

Liver Transpl. 2017 Nov;23(11):1415-1421. doi: 10.1002/lt.24832.

PMID:
28752920
27.

Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention.

Reb A, Ruel N, Fakih M, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V.

Eur J Oncol Nurs. 2017 Aug;29:125-134. doi: 10.1016/j.ejon.2017.06.003. Epub 2017 Jun 19.

PMID:
28720259
28.

Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.

Wood K, Byron E, Janisch L, Salgia R, Sharma MR.

Am J Clin Oncol. 2017 Jun 26. doi: 10.1097/COC.0000000000000400. [Epub ahead of print]

PMID:
28654574
29.

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.

Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC.

Oncogene. 2017 Sep 7;36(36):5219. doi: 10.1038/onc.2017.203. Epub 2017 Jun 19.

30.

Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer.

Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D.

Oncol Lett. 2017 Jun;13(6):4027-4034. doi: 10.3892/ol.2017.5956. Epub 2017 Mar 29.

31.

Value-Based Medicine and Integration of Tumor Biology.

Brooks GA, Bosserman LD, Mambetsariev I, Salgia R.

Am Soc Clin Oncol Educ Book. 2017;37:833-840. doi: 10.14694/EDBK_175519. Review.

32.

Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.

Zhang K, Wang J, Tong TR, Wu X, Nelson R, Yuan YC, Reno T, Liu Z, Yun X, Kim JY, Salgia R, Raz DJ.

Int J Cancer. 2017 Aug 15;141(4):766-777. doi: 10.1002/ijc.30769. Epub 2017 May 31.

PMID:
28481029
33.

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.

Cancer Treat Rev. 2017 Apr;55:181-189. doi: 10.1016/j.ctrv.2017.03.006. Epub 2017 Mar 30. Review.

34.

Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.

Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK.

Oncotarget. 2017 Jul 4;8(27):43733-43751. doi: 10.18632/oncotarget.16376.

35.

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.

Salgia R.

Mol Cancer Ther. 2017 Apr;16(4):555-565. doi: 10.1158/1535-7163.MCT-16-0472. Review.

36.

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.

Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC.

Oncogene. 2017 Aug;36(31):4526. doi: 10.1038/onc.2017.77. Epub 2017 Apr 3.

37.

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Polzer J, Flynt A, Raddad E, Peek VL, Wijayawardana SR, Um SL, Gross S, Connelly MC, Morano C, Repollet M, Sanders R, Baeten K, D'Haese D, Spigel DR.

Invest New Drugs. 2017 Jun;35(3):334-344. doi: 10.1007/s10637-017-0446-z. Epub 2017 Mar 15.

38.

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.

Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DR.

Lung Cancer. 2017 Mar;105:7-13. doi: 10.1016/j.lungcan.2016.12.020. Epub 2016 Dec 31.

PMID:
28236984
39.

Predictors of Waitlist Mortality in Portopulmonary Hypertension.

DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN.

Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.

40.

Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.

Gong J, Cho M, Sy M, Salgia R, Fakih M.

Oncotarget. 2017 Jun 27;8(26):42198-42213. doi: 10.18632/oncotarget.15030.

41.

TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.

Park JH, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y.

Cancer Sci. 2017 Mar;108(3):488-496. doi: 10.1111/cas.13160.

42.

Genomic mutation-driven metastatic breast cancer therapy: a single center experience.

Yuan Y, Yost SE, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J.

Oncotarget. 2017 Apr 18;8(16):26414-26423. doi: 10.18632/oncotarget.14476. Erratum in: Oncotarget. 2017 Sep 22;8(37):62817.

43.

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.

Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL.

Sci Signal. 2017 Jan 3;10(460). pii: eaag1064. doi: 10.1126/scisignal.aag1064.

PMID:
28049763
44.

A Rare Case of Gastric Variceal Hemorrhage Secondary to Infiltrative B-Cell Lymphoma.

Lenhart A, Fernandez-Castillo J, Mullins K, Salgia R.

Case Rep Gastroenterol. 2016 Oct 6;10(3):518-524. eCollection 2016 Sep-Dec.

45.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.

Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.

PMID:
27836716
46.

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.

Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R.

Sci Rep. 2016 Sep 13;6:32992. doi: 10.1038/srep32992.

47.

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.

Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A, Salgia R.

Oncotarget. 2016 Oct 11;7(41):66880-66891. doi: 10.18632/oncotarget.11801.

48.

MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.

Sattler M, Salgia R.

J Thorac Oncol. 2016 Sep;11(9):1381-3. doi: 10.1016/j.jtho.2016.07.003. No abstract available.

49.

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.

Won B, Mambetsariev I, Salgia R.

BMC Cancer. 2016 Aug 2;16:568. doi: 10.1186/s12885-016-2636-z.

50.

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY.

Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19.

PMID:
27450722

Supplemental Content

Loading ...
Support Center